We provide you with 20 years of free, institutional-grade data for RLYB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RLYB. Explore the full financial landscape of RLYB stock.
| Reported Date | CIK | Ticker | Type |
|---|
Rallybio Corporation(NASDAQ:RLYB) 
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead program is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for t...
Share this website to your friends
The information provided in this report about RLYB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.